| Table of Contents |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Synthetic M13 phage engagers expand CAR-T cell antigen recognition to overcome tumor heterogeneity |
| Fan Feng, Xu Han, Zezheng Fang, Kaiyan Xi, Zixu Wang, Jianyu Shen, Yi Zhang, Mingrui Wang, Zhiqiang Li, Xuan Han, Kaijie Zhao, Huimin Geng, Yanrong Zhang, Wenli Zhang, Zimei Wu, Songbai Gui, Yulin Zhang, Shilei Ni |
|
|
|
|
| Breaking the immunosuppressive barrier: an armored CAR-M biotechnology with the original M1 phenotype dominance rescues antitumor immunity |
| Fuyu Du, Yuanhui Xu, Wenhui Chu, Jingjing Qiu, Meixi Jiang, Xinruo Wang, Dashan Guan, Maozhi Su, Anna He, Zixuan Ye, Yuqiong Xia, Xianghan Zhang, Zhongliang Wang, Pengbo Ning |
|
|
| Engineered phage-derived lysins effectively kill mycobacterial pathogens |
| Adel Abouhmad, Jana Kassaliete, Camilla Davids, Dennis Grimon, Tarek Dishisha, Karim Abdelkader, Zienab E. Eldin, Mats Clarsund, Yves Briers, Gabriela Godaly, Rajni Hatti-Kaul |
| Open Access |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|